EP3452589A1 - Method and system for magnetic extraction of components in a liquid sample - Google Patents
Method and system for magnetic extraction of components in a liquid sampleInfo
- Publication number
- EP3452589A1 EP3452589A1 EP16801505.5A EP16801505A EP3452589A1 EP 3452589 A1 EP3452589 A1 EP 3452589A1 EP 16801505 A EP16801505 A EP 16801505A EP 3452589 A1 EP3452589 A1 EP 3452589A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pipette
- cone
- phase
- holder
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000005291 magnetic effect Effects 0.000 title claims description 62
- 238000000034 method Methods 0.000 title claims description 51
- 239000007788 liquid Substances 0.000 title claims description 32
- 238000000605 extraction Methods 0.000 title description 40
- 239000012472 biological sample Substances 0.000 claims abstract description 12
- 239000002245 particle Substances 0.000 claims description 73
- 239000006249 magnetic particle Substances 0.000 claims description 66
- 238000005406 washing Methods 0.000 claims description 52
- 239000000523 sample Substances 0.000 claims description 44
- 239000008188 pellet Substances 0.000 claims description 29
- 238000011084 recovery Methods 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 16
- 238000012546 transfer Methods 0.000 claims description 16
- 230000005012 migration Effects 0.000 claims description 14
- 238000013508 migration Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 12
- 230000005499 meniscus Effects 0.000 claims description 11
- 244000005700 microbiome Species 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 7
- 238000013519 translation Methods 0.000 claims description 6
- 238000006073 displacement reaction Methods 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 35
- 238000010828 elution Methods 0.000 description 17
- 239000011534 wash buffer Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000011536 extraction buffer Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 6
- 238000010009 beating Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012149 elution buffer Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 235000011034 Rubus glaucus Nutrition 0.000 description 3
- 235000009122 Rubus idaeus Nutrition 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 244000291564 Allium cepa Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- 244000235659 Rubus idaeus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108700010839 phage proteins Proteins 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000710185 Mengo virus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 241001135268 Salmonella enterica subsp. enterica serovar Derby Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005293 ferrimagnetic effect Effects 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/1013—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/02—Apparatus for enzymology or microbiology with agitation means; with heat exchange means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/02—Burettes; Pipettes
- B01L3/021—Pipettes, i.e. with only one conduit for withdrawing and redistributing liquids
- B01L3/0217—Pipettes, i.e. with only one conduit for withdrawing and redistributing liquids of the plunger pump type
- B01L3/0231—Pipettes, i.e. with only one conduit for withdrawing and redistributing liquids of the plunger pump type having several coaxial pistons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/02—Burettes; Pipettes
- B01L3/0275—Interchangeable or disposable dispensing tips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
- B01L3/50853—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates with covers or lids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L9/00—Supporting devices; Holding devices
- B01L9/52—Supports specially adapted for flat sample carriers, e.g. for plates, slides, chips
- B01L9/523—Supports specially adapted for flat sample carriers, e.g. for plates, slides, chips for multisample carriers, e.g. used for microtitration plates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L9/00—Supporting devices; Holding devices
- B01L9/54—Supports specially adapted for pipettes and burettes
- B01L9/543—Supports specially adapted for pipettes and burettes for disposable pipette tips, e.g. racks or cassettes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0609—Holders integrated in container to position an object
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0848—Specific forms of parts of containers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
Definitions
- the invention relates to the field of extracting components contained in a solution using magnetic particles.
- the invention finds particular application in the field of biological sample preparation, especially in the implementation of in vitro diagnostics, by the capture of analytes of biological origin (nucleic acids, microorganisms, proteins, peptides, etc.). ) present in a solution.
- analytes of biological origin nucleic acids, microorganisms, proteins, peptides, etc.
- the "BOOM®” technology consists in introducing into a liquid sample magnetic particles capable of binding with components of interest, then to separate the magnetic particles from the sample using one or more magnets. The particles thus captured can then undergo further processing, for example to release their components in a recovery solution. Because of the efficiency of this technique, many devices have been developed and marketed, especially for DNA and RNA, 7-9, both manual devices (for example the applicant's NucliSENS-miniMAG®) and devices automated systems (NucliSENS-easyMAG® of the applicant). These automated devices, however, suffer from various limitations.
- a first limitation concerns their versatility and their size. Indeed, these devices are most often heavy and bulky automata that are designed to implement a non-modifiable treatment sequence by the user. An automaton is thus designed for a single type of extraction, for example designed for the purification of nucleic acids but unable to implement a magnetic immuno-concentration.
- a second limitation relates to the injection and suction circuits of the different liquids used during the extraction.
- the number of liquids being important, this involves circuits that are also numerous and / or complex.
- these injection / suction circuits must be regularly cleaned, which involves the disabling of the devices.
- a third limitation relates to the brewing operations that are implemented to obtain the homogeneity of the sample comprising the magnetic particles before capture, to maximize the capture by them of the analytes of interest or to effectively wash the magnetic particles. This type of mixing usually requires complex mechanisms, for example based on mobile magnets that set the magnetic particles in motion.
- the fourth limitation concerns the different liquids used during extraction.
- the steps implemented for the extraction are carried out in one or from a single container.
- this container sets an identical volume for all the liquids involved (e.g. the sample, the different washing solutions, the elution solution, etc.), which limits the overall efficiency of the extraction process. Indeed, some treatments (e.g. washing) require large volumes to be fully effective while other treatments are content with a small volume of liquid (e.g., elution).
- the object of the present invention is to provide a method of extracting components in a liquid sample using magnetic particles which offers a great freedom in the choice of liquid volumes, in particular up to 10 ml, used during extraction.
- the subject of the invention is a process for extracting components contained in a biological sample in liquid form, said components being capable of being fixed on magnetic particles, the process comprising:
- a suction phase of the mixture from a well in a tubular pipette cone comprising a tip intended for liquid pipetting
- a phase of capture of the magnetic particles on an inner wall of the pipette cone by applying a first magnetic field to the pipette cone, said field being able to attract and hold the magnetic particles in a predetermined zone of the pipette cone, so-called of "capture", above the tip of it;
- the invention takes advantage of a pipette cone in which suction and discharge cycles can be performed by dipping its tip in a well.
- suction and discharge cycles can be performed by dipping its tip in a well.
- the volume of the recovery solution may therefore be small if necessary.
- the volume of the recovery solution is thus independent of the volume of the sample and the volume of the pipette cone in which the extraction is carried out. Thanks to the invention, it is therefore possible to optimize each volume of liquid used, and thus optimize extraction.
- the displacement of the first magnetic field consists in moving the pipette cone parallel to a longitudinal axis of said cone, and in keeping the first magnetic field constant, the longitudinal axis of the pipette cone remaining equidistant from the first one; magnetic field when moving the pipette cone.
- the migration of the particles can be carried out in a simple manner by moving the pipette cone relative to, for example, a permanent magnet.
- the transfer phase comprises:
- the second magnetic field is produced by a magnet positioned partially or wholly under the tip of the pipette cone.
- the first magnetic field applied to the pipette cone is disabled upon application of the second magnetic field.
- the second magnetic field makes it possible to simply attract the particles into the recovery well, which increases the rate of recovery of the magnetic particles in the recovery well, as well as the number of particles recovered.
- the second magnetic field automatically captures the magnetic particles in the recovery well. For example, if the recovery solution is an eluent, the particle-bound components have been released and a technician can directly pipet the solution which is devoid of magnetic particles.
- the transfer phase comprises the deactivation of the first magnetic field followed by the application of suction and discharge cycles of the solution of the recovery well in the tip of the pipette cone, said application comprising:
- the first phase effectively breaks up the cluster of particles captured on the pipette cone, also called "pellet", and thus resuspend the particles in the recovery solution.
- the second phase allows to continue stirring the solution while not preventing the migration of particles under the effect of the magnetic field. This makes it possible to further increase the recovery rate and the number of particles recovered in the recovery well.
- the solution is an eluent whose function is to release the components captured by the magnetic particles, these cycles have the effect of stirring the particles in the eluent, which increases the effectiveness of the eluent, in particular when using an elution solution in the stall of magnetic particle analytes without heating step.
- the method comprises, prior to the capture phase, a stirring phase of the mixture contained in the pipette cone by the application of at least one suction and discharge cycle of said mixture in the cone pipette. Due to the cone geometry, tubular shape, it is possible to obtain a large volume flow rate to the section of the cone, and therefore effective mixing. In addition, there is great turbulence in the cone naturally generated by the flow of liquid, turbulence that increase the efficiency of the brewing. Advantageously, a disposable accessory is provided in the cone to increase this effect.
- the method comprises, prior to the transfer phase, at least one washing phase of the particles captured on the inner wall of the pipette cone by: - deactivating the magnetic field;
- the release of the captured particles comprises a phase of applying the cycles so as to reciprocate a meniscus of said solution on a pellet of particles captured in the pipette cone. and-coming of said meniscus being made on a portion of the cone lower than the total length of the pipette cone.
- the release of the captured particles comprises a second phase of application of the cycles so as to completely suck up and discharge the washing solution of the cone.
- the frequency of application of the cycles of the second phase is lower than the frequency of application of the cycles of the first phase.
- the method comprises at least two washing phases implemented in two separate washing solutions.
- the components contained in the biological sample are nucleic acids (eg DNA, RNA).
- the components contained in the biological sample are microorganisms (eg bacteria, fungi, yeasts), and wherein the method comprises a single capture phase and a single wash phase.
- the mixture of the sample with the magnetic particles has a volume greater than 1 milliliter, and preferably greater than or equal to 2 milliliters, and in which the volume of the recovery well is less than or equal to 200 micro liters, and preferably less than or equal to 100 micro liters.
- the method comprises, prior to the transfer phase, at least one washing phase of the particles captured on the inner wall of the pipette cone by: drawing the washing solution into said pipette cone;
- the modulation of the magnetic field induces a reorganization of the particle pellet captured on the wall of the cone.
- the base can change shape, spread, slide or "roll" on the wall of the pipette cone. This reorganization of the base makes it possible to further increase the effectiveness of the washing, and all the more so since this reorganization can be implemented in conjunction with suction and discharge cycles of the washing solution.
- the modulation of the first magnetic field is carried out:
- the modulation is obtained simply, for example by a technician who slides a bar of magnets or by a PLC which puts a simple mechanism of translation of a bar of magnets.
- the volume of the pipette cone is at least ten times greater than the volume of the recovery well.
- the volume of the mixture is at least three times greater than the volume of the pipette cone.
- the components belong to the group consisting of single-stranded or double-stranded nucleic acids (DNA and / or RNA), microorganisms, proteins, and peptides. The components consist of all other types of molecules depending on the functionalization given to the magnetic particles.
- the object of the present invention is also to provide a device for implementing the method just described, which is compact and easy to use by a laboratory technician.
- the invention also relates to a pipette holder comprising:
- a pipette holder comprising a first housing in which is insertable, advantageously removably, a pipette equipped with at least one tubular pipette cone comprising a tip for liquid pipetting, the first housing being open on the recess of the base, the pipette holder being movable in translation relative to the base in a direction parallel to an axis of the pipette cones and movable between a first position in which the tip of each pipette cone is housed in a well of the support of well and at least a second position in which said tip is outside said well;
- a second housing adapted to releasably receive a magnetized part, the second housing facing each of the pipette tips in a position above the tip thereof when the pipette holder is in the first position, and the second housing faces the tip of the pipette cone when the pipette holder is in the second position.
- the pipette holder receives a pipette and the technician implements the steps of the extraction process, up / down the pipette, in particular to migrate the particle pellet in the tip of the cone (s). pipette, introducing wells (in the form of plate, bar, etc.) into the base, and actuating the pipette.
- the pipette holder which is compact and transportable, also allows semi-automation of the extraction process when an electronic pipette is used.
- a pipette comprises indeed suction and discharge circuits in each pipette cone equipping it, and a microprocessor-based electronic circuit.
- This electronic circuit controls the suction / discharge circuits according to instructions entered by the technician by means of an interface fitted to the pipette and / or a computer / tablet / smartphone connected to the pipette (eg via a wireless link Of type bluetooth), etc.
- These instructions consist, for example, of instructions for suction / discharge cycles and / or of a choice of a particular protocol pre-recorded in the pipette.
- the electronic pipette is programmable, great versatility is furthermore obtained in the definition of the extraction process, which can be adapted according to a particular desired magnetic capture (eg: purification of nucleic acids, magnetic immunoconcentration ,. ..).
- a suitable protocol for the targeted extraction can be recorded in the pipette, the protocol being defined in terms of the number of suction and discharge cycles, the sequence of cycles, the frequency of cycles, the duration between cycles. , defined volumes, etc.
- the first housing includes an opening for the front insertion and withdrawal of the pipette into the first housing of the pipette holder.
- the front insertion and removal of the pipette and cones in place minimizes the risk of touching the pipette holder with cone tips, and thus the risk of contamination of the pipette holder.
- the second housing is made in the base.
- the pipette holder has a third housing in which the magnetized piece is removable to face each pipette cone at a position above the tip of said cone when the pipette holder is in the second position.
- the magnetized part e.g. comprising one or more permanent magnets
- the magnetized part is integral with the pipette tips and therefore follows their translational movement relative to the base. During such movements, the magnetized part thus retains the pellets of magnetic particles fixed in the cones.
- the technician can for example mount the pipette to more easily move a well support in the base without the risk of moving the pellets of particles in the cones.
- the second and third housings communicate, and the pipette support comprises means able to removably hold the magnetized part in the third housing.
- the technician can detach the magnetized piece from pipette holder which then automatically takes place in the base by falling into the second housing. This detachment in particular takes place for the migration operation of the magnetic particles in the tips of the cones.
- the base comprises at least one rotating gear wheel
- the pipette holder comprises a rack cooperating with the gearwheel to translate the pipette holder relative to the base during rotation of the gearwheel.
- the pipette holder comprises a device for locking and unlocking the pipette holder in the first position.
- the pipette holder comprises at least one handle secured to the toothed wheel to rotate it and adapted to be removably attached to a handle secured to the gear wheel of another pipette holder, which therefore allows to increase the number of pipette tips during the extraction process.
- the invention also relates to a system for extracting components contained in a biological sample in liquid form, said components being capable of being fixed on magnetic particles, the system comprising:
- a pipette equipped with at least one tubular pipette cone comprising a tip intended for liquid pipetting and a suction and discharge circuit in each pipette cone;
- a pipette holder comprising:
- a pipette support comprising a first housing in which the pipette is inserted, advantageously removably, the first housing being open on the recess of the base, the pipette support being movable in translation relative to the base in a direction parallel to an axis of the pipette cones and movable between a first position in which the tip of each pipette cone is housed in a well of the well holder and at least a second position in which said tip is out of said well;
- the pipette holder is in accordance with the pipette holder described above.
- the invention also aims to provide a well support for the migration of magnetic particles from tips of pipette cones in recovery wells.
- the invention also relates to a well support, comprising a part in which are formed recesses for receiving the wells, and at least one magnet facing each of the recesses formed in said part.
- Figure 1 is a perspective view of an extraction system according to the invention
- FIGS. 2A and 2B are front and perspective views of an electronic pipette and its removable pipette tips
- FIGS. 3A and 3B are perspective and front views of a pipette holder according to the invention.
- FIGS. 4A and 4B are a detail sectional view of the pipette holder of FIG. 3, respectively along the planes A-A and B-B of FIG. 3B;
- Figure 5 is a perspective view of a deepwell plate including wells
- Figures 6A and 6B are perspective views of a magnetic rack and PCR elution tubes that can be accommodated in the rack;
- Figure 7 is a front view of a magnetized part according to the invention.
- Figure 8 is a flow chart of an extraction process according to the invention.
- Figure 9 is a photograph of the pipette tips of a system according to the invention with pellets of magnetic particles placed about halfway up the cones;
- FIG. 11 is a photograph of PCR elution tubes in which the magnetic particles have been recovered:
- Figures 12 and 13 illustrate a second embodiment of the pipette holder according to the invention
- Figure 14 is a perspective view of two systems according to Figure 1 coupled by means of rotation handles;
- Figure 15 is a schematic view illustrating the reciprocation of a meniscus of a solution on a particle pellet to detach the latter from the wall of a pipette cone. Except for Figure 15, the description is made in relation to plans and photographs on a reduced scale of a real system.
- a system 10 for extracting (FIG. 1) components contained in a liquid sample comprises an electronic pipette 12 (FIG. 2), a pipette holder 14 (FIGS. ) in which the pipette 12 is housed, one or more well supports 18a, 18b (FIGS. 5 and 6) can each be housed in the pipette holder 14, and a first magnetized piece 16 (FIG. 7).
- the pipette 12 which is portable, comprises a row of pipette tips 20, and a body 22 on which the cones 20 are mounted (FIG. 2A).
- a liquid suction / discharge circuit in the cones 20 for example a set of pistons actuated by an electric motor
- an electronic control circuit of the suction / discharge circuit for example a set of pistons actuated by an electric motor
- the electronic circuit which comprises for example a microprocessor and one or more computer memories, is programmable, and embeds instructions for the implementation of one or more pipetting protocols, each protocol comprising one or more steps.
- the electronic circuit also comprises a man-machine interface 24 housed in a handle 26 of the body 22, the interface comprising a set of selection and navigation buttons 28 and a display screen 30 allowing the display and selection of different control protocols. pipetting recorded.
- the user can in particular program the electronic pipette 12, eg by downloading instructions therefrom from a computer connected to the pipette 12 through a wireless link, for example Bluetooth.
- the user can also select, via the interface 24, a prerecorded protocol.
- the pipette 12 is also able to suck up a predefined volume of liquid in each of the cones 20, to discharge a predefined volume from each of the cones, to implement automatic suction / discharge cycles of variable duration and frequency. As illustrated more particularly in FIG.
- each cone 20 has at its open pipetting end a tapered profile 21, or "tip". This portion 21 has a reduced section in a plane perpendicular to the X axis, which allows its introduction facilitated in containers or wells as is known per se.
- the electronic pipette 12 is for example the "VIAFLO II 8-channel" model marketed by the company ⁇ INTEGRA Biosciences AG, Switzerland, the model of which elements are described in the patent applications US 2009/071266, US 2009/074622, US2011076205 and US 2008/095671.
- the pipette holder 14 comprises meanwhile (FIGS. 3A and 3B) a base 34 intended to be placed on a work surface (eg a laboratory table or bench) and a mobile part 36 with respect to the base. 34.
- the mobile part 36 also called “pipette holder”, comprises a housing 38 in which the pipette 12 can be removably inserted and kept stationary as illustrated in FIG. 1.
- the support 36 comprises one or more racks 40, for example two in number, meshing with gear wheels 42 mounted on a shaft 44 rotatable and housed in the base 34.
- One or more rods 46 are furthermore fixed to the support 36 (or in the base 34) and slide in orifices of the base 34 (or in the support 36), in order to guide the support 36 in its translational movement.
- One or two rotational handles 50 are further attached to the end of the shaft 44 to allow the user to easily turn the latter according to the arrows 52 ( Figure 1) and thus raise and lower the pipette holder 36 as as illustrated by the arrows 54 ( Figure 1).
- the translational movement of the pipette holder 36 relative to the base 34 is therefore parallel to the axis X of the cones 20 when the pipette 12 is placed in the housing 38 of the support 36, and therefore parallel to the direction of gravity when the base 34 is placed on a horizontal work plane, so that the support 36 "up” or "down".
- the base 34 is open on its front face 56 to allow the introduction and removal of the well supports 18a, 18b, thus defining a housing for the latter.
- This housing is open on its upper part to allow the cones 20 of the pipette 12 to reach said well supports when the pipette goes down.
- the pipette 12 can take several positions relative to the base 34, and thus with respect to a well support 18a, 18b housed in the latter.
- the pipette 12 can take a position in which the tips 21 of the cones 20 dipped in wells of the support 18a, 18b, and at least one position in which the tips 21 do not dip in the wells, and are at a distance from the latter to allow the handling of well supports by the user and the capture of magnetic particles in a central position of the cones 20.
- a well support is a compartmentalized plate 18a (FIG. 5), usually called a "microplate” of the "DeepWell” type.
- This type of plate comprises rows 60 of wells 52 in which can dip the row of pipette cones 20. Each row 60 can thus receive a particular liquid used during the extraction step implemented by the system 10. Passage from one row 60 to the other is then achieved simply by the user who puts the pipette cones 20 above the particular row 60 containing the liquid necessary for the step to be implemented.
- the support 18b comprises for this purpose a body 64 in which is formed a row of housing 66 capable of receiving the row of pipette cone 20, and in which is housed a second magnetized piece 68 comprising one or more permanent magnets, for example a permanent magnet near each well 66.
- the magnetized piece 68 is placed under the wells 66 or in front of their lower portions as illustrated.
- the tips 21 of the pipette cones 20 are placed above the magnetized part 68 when said tips are immersed in the wells 66.
- the support 18b serves as a magnetic rack removably removably tubes 69 in the housings 66 , for example, PCR elution tubes as illustrated in FIG. 6B, for purposes of, for example, subsequent transfer of the recovered extraction product thereinto.
- the first magnetized piece 16 the function of which is to capture magnetized particles in the cones 20 in a manner described in more detail later, comprises one or more permanent magnets 72, advantageously a row of separate permanent magnets. each other by spaces 74, and still more advantageously a permanent magnet opposite each pipette cone 20 when the part 16 is completely housed in the base 34.
- the part 16 further comprises a handle 76 for better grip by the user.
- a housing 78 for receiving the magnetized part 16 is provided in the base 34, the housing 78 being placed so that the part 16 faces the pipette cones 20 above their point 21, and preferably facing a central zone 80 at a height greater than the well, when the tips 21 are immersed in the wells maintained in a well support. In this way, the particles are captured in a volume of the cone large enough not to form plugs in the cones.
- the pipette holder 14 also comprises means making it possible to control the rate of rise of the support 36.
- the rack and the gearwheel are designed so that a half-turn (180 °) of the wheel 50 makes it possible to traverse the assembly of the rack, and a counterweight 58 integrated in each of the handles 50 off-axis relative to the shaft 44.
- These weights under their weight and the associated leverage, generate a rotational torque rotating the 44 while limiting the torque transmitted by hand by the user.
- a substantial part of the shaft 44 is also formed of a half-cylindrical weight for the same purpose. This mechanical assistance helps lift the pipette holder, and therefore limits musculoskeletal disorders, and implements a brake that allows the user to control more accurately the rate of rise and fall of the support 36.
- the weight 59 comprises a magnetizable material (eg steel or equivalent) and a third magnetized piece 80 (parallelepipedal or in the form of a circular arc concentric with the shaft 44) is housed in the base 34, preferably opposite the magnetized part 16 vis-à-vis the shaft 44 to not disturb the extraction.
- the flyweight 59 of the shaft passes in front of the magnetized part 80, the rotational movement of the shaft 44 is slowed down because of the braking torque generated.
- a stop mechanism is also advantageously provided as illustrated in FIG. 4B.
- a wheel 84 of deformable material eg elastomer
- a protrusion 82 for example hemispherical, is also projecting from the base 84 in front of the wheel 84.
- the first tooth 86 meets the protrusion 82.
- the tooth 86 bends, passes the protrusion 82, and returns to its shape .
- the tooth 86 can then rest on the protrusion 82, the hardness of this tooth being chosen so that it does not bend under the action of the weight of the pipette 12 and the pipette holder 36.
- the pipette is thus blocked in the high position, the user can therefore release the wheel 50.
- the second tooth 88 of larger size (eg length and / or width) requires for its passage a much larger torque, and thus defines a stop to prevent that the pipette holder 36 does not disengage the base 34, unless the user deploys a force capable of breaking this tooth.
- the protuberance 82 is replaced by a stop having a ball spring-loaded in a housing of the base.
- the wheel 84 can thus be made of a hard material.
- the action of the first tooth 86 then has the effect of pushing the ball into its housing, thus allowing the passage of the tooth 86.
- Magnetic particles are captured sequentially in the pipette tips during suction / discharge cycles over the entire volume of sample to be treated.
- a process for purification of viral nucleic acids using NucliSENS ⁇ chemistry namely a nucleic acid extraction using magnetic silica particles.
- the process starts with a step 100 of preparation of the different samples and reagents necessary for the purification, followed by said purification at 102.
- the preparation 100 consists, in 104, of mixing the biological sample comprising viruses from which it is desired to extract the nucleic acids, with a reagent for chemical lysis of viruses (eg bioMérieux's "Nuclisens miniMAG” lysis reagent, reference 200292, or bioMérieux's "Nuclisens easyMAG” lysis reagent, reference 280130), in two volumes of lysis reagent for a sample volume.
- the mixture is then heated for 30 minutes at 56 ° C, thereby releasing the nucleic acids from the viruses in a manner known per se.
- Magnetic silica particles eg particles having a paramagnetic core, ferromagnetic or ferrimagnetic having or not a remanence, covered with a silica shell, having the property of binding with nucleic acids, are then introduced, at 106, in the lysed sample.
- Preparation 100 continues, at 108, by filling the microplate 18a, having wells 62 of 5mL, and PCR elution tubes 69 of 0.2ml of the magnetic rack 18b so that:
- each well in the first row of the microplate 18a is filled with the lysed sample comprising the silica particles, hereinafter "lysed sample".
- the total volume in each well of the first row is preferably greater than 1.5 mL due to the use of the Deepwell 5 mL microplate and volumes handled by the electronic pipette; each well 66 of the second row of the microplate 18a is filled with 1250 ⁇ of wash buffer (eg BioMérieux's "NucliSENS easyMAG Extraction Buffer No. 2" reference bMx 280131);
- each well 66 of the third row of the microplate 18a is filled with 1250 ⁇ of wash buffer (e.g. the bioMérieux NucliSENS easyMAG Extraction Buffer # 2 reference bMx 280131);
- wash buffer e.g. the bioMérieux NucliSENS easyMAG Extraction Buffer # 2 reference bMx 280131;
- each PCR elution tube 69 housed in the magnetic rack 18b is filled with a volume of 100 elution buffer (e.g. the "NucliSENS easyMAG Extraction Buffer No. 3" from bioMérieux, reference 280132).
- 100 elution buffer e.g. the "NucliSENS easyMAG Extraction Buffer No. 3" from bioMérieux, reference 280132.
- Extraction 102 begins with homogenization of the lysed sample. To do this, the magnetized part 16 is not placed in the base 34 and therefore does not interfere with the cones 20. The user rotates one of the wheels 50 so as to immerse the tips 21 of the cones 20 in the row of plate well 18a comprising the lysed sample. Then, using the interface 24 of the pipette 12, it selects a first pipetting protocol comprising at least one suction / discharge phase of the lysed sample in the cones 20, and starts the selected protocol. These phases (e.g. two in number) each comprise at least one suction / discharge cycle (e.g. five cycles) followed by a waiting time of several minutes, for example 5 minutes. For the purposes of the invention, a suction and discharge cycle consists of filling at least three quarters, for example completely, the cones and emptying them completely, unless otherwise specified by the program.
- a suction and discharge cycle consists of filling at least three quarters, for example completely, the cones and emptying
- the cones 20 are empty and their tips 21 dive into the wells containing the lysed sample.
- the purification 102 is continued by the capture, at 112, of the silica particles of the lysed sample on the inner wall of the cones 20.
- the user places the magnetized part 16 in the housing 78 of the base 34, selects using the interface 24 of the pipette 12 a second pipetting protocol then starts the selected protocol.
- the second protocol comprises a plurality of suction cycles / waiting / repression, eg a dozen cycles, a suction being separated from a discharge of a few seconds, eg ten seconds.
- a part of the particles contained in the lysed sample is captured on the wall of the pipette cones by virtue of the magnetic field produced by the magnetized part 16.
- the magnetic particles, and thus also their bound nucleic acids, are thus captured in the form of pellets of particles 100 in front of the magnetized part 16, and preferably on a central zone halfway up the cones 20, as illustrated in FIG. FIG. 9.
- the user raises the pipette holder 14 (resp., raises the pipette 12) so as to release the plate 18a from the cones 20, aligns the second row of the plate 18a with the cone row 20 and then places the pipette holder (resp. the pipette) so as to soak the tips 21 of the cones in the wells of the plate 18a.
- the user selects, using the interface 24, a third pipetting protocol comprising at least one suction / discharge phase of the lysed sample in the cones 20, then initiates the selected protocol.
- the third protocol is for example identical to the first protocol. The repeated passage of the washing buffer on the pellets of particles thus makes it possible to wash the latter.
- This washing step is advantageously completed, or implemented in conjunction with, a modulation of the magnetic field capturing the particles on the cones.
- the user raises and lowers the pipette 12, which has the effect of moving the pellets of particles on the cones, or the magnetized part 16 comprises a train of permanent magnets and the user slides in a reciprocating the magnetic part 16 of its housing 78, so that the intensity and the magnetic field lines capturing the pellets vary, while retaining the particles captured on the cones.
- the modulation of the magnetic field has the effect of rearranging the pellets during washing, and increase the efficiency thereof.
- a second wash is then implemented at 116 using the washing buffer of the third row of the plate 18a. For example, the cones are completely emptied of the first wash buffer, then a second wash identical to the first wash is performed.
- a migration step 118 of the pellets of particles 200 in the tips 21 of the cones 20 is implemented.
- the cones 20 are preferably filled with the second washing buffer to facilitate the sliding of the caps 200 and remain aligned with the second row of the plate 18a.
- the user then rotates one of the wheels 50 to raise the pipette 12.
- the magnetized part 16 being secured to the base 34, the caps therefore remain immobile relative to the latter and migrate to the tips 21 by sliding on the walls of the cones 20 as the pipette rises.
- one of the washing phases or an additional washing phase, consists in removing the magnetized part so as to release the magnetic particles and carry out a washing while stirring the particles in the washing solution by suction and discharge cycles. .
- the particles are then captured again by repositioning the magnetized part and carrying out suction and discharge cycles as previously described.
- the purification 102 ends with a step 120 of transfer in the PCR elution tubes 69 of the magnetic particles present in the tips 21 of the cones 20.
- the user lifts the pipette holder 14, removes the plates 18a,
- the magnetic rack 18b is placed in the housing 56 so as to align the PCR tubes 69 with the row of cones 20, the pipette holder 14 is rested and the magnetized piece 16 is removed from the base 14 in order to release the magnetic particles captured from the cones.
- the user selects, using the interface 24, a fourth pipetting protocol, then launches the selected protocol.
- a first variant of this protocol consists of suction and discharge cycles of the elution buffer in the tips 21 of the cones 20, which allows the resuspension of the magnetic particles by breaking the pellets of particles.
- the frequency chosen for the cycles allows, at each discharge in the tubes 69, a portion of the magnetic particles to be captured in the tubes 69 by the magnetic field of the magnetized piece 68 housed in the rack 64. These cycles make it possible to "rinse" the tips 21 to recover particles adhering to the walls of the cones.
- suction and discharge cycles are first implemented at a higher frequency so as to stir more vigorously the buffer and the particles, and thus to obtain an accelerated homogenization facilitating the transfer to the elution tubes 69.
- the transfer step ends with the complete discharge of the elution buffer into the tubes 69.
- the magnetic particles are then permanently separated from the buffer Elution, as illustrated in Figure 11.
- the user can thus recover the tubes 69 for further processing, in particular the elution of nucleic acids by heating, in a manner known per se.
- the magnetized piece 16 is housed in the base 34. Also, when the user wishes to advance the plate 18a, it can raise the pipette high enough to carry out this operation. This causes, as for the migration of particles to the tips, the displacement of the caps 200 on the walls of the cones 20, which has the advantage of "rearrange" the caps that can roll on themselves. The effectiveness of the washing is thus reinforced. However, this implies that the user is careful never to go up the pipette too much to avoid the pellets coming out of the cones. To do this, the user can for example lift or tilt the pipette holder to keep the caps away from the openings of the cones.
- a second embodiment of the pipette holder according to the invention allows the handling of the plates 18a, 18b by raising only the pipette, and therefore avoiding lifting the pipette holder 14, while ensuring that the pellets of particles remain at a distance. tips 21 of the cones.
- This second embodiment differs from the first embodiment by the means for receiving the workpiece.
- the base 34 comprises the housing 78 for the insertion and removal of the magnetized part 16 as previously described and the housing 78 is open in its upper part 130 to also allow insertion. and the removal of the piece 16 vertically in the housing 78.
- the pipette holder 36 further comprises means for fixing the magnetized piece 16 in line with the open housing 78, in particular one or more pads 132 of magnetizable material (eg steel) attached to a rear wall 134 of the movable pipette holder 36 (Fig. 12C).
- the magnetized piece 16 is integral with the movable support 36, and remains opposite the cones 20 when the user moves up and down the pipette (in particular during the washing phases), as illustrated in FIGS. 12B to 13 A.
- the user disconnects the magnetized piece 16 from the pipette holder 36, by simply pressing down on the handle 78 of the piece 16 and raises the pipette 12.
- the magnetized part 16 is detached from the studs 134, thus remains in the housing 78 of the base and is thus integral with the base 34, inducing the migration of the caps 200 in the tips 21 of the cones as previously described ( Figures 13A and 13B).
- the user replaces the plate 18a by the rack 18b equipped with PCR elution tubes, removes the magnetized part 16 and down the pipette ( Figure 13C, tubes 69 not shown).
- the pipette holder 36 may include a housing similar to the housing 78 of the base in which the user slides the magnetized part including the wash phases.
- a particular extraction process has been described. The present invention, however, applies to any type of capture of magnetic particles and to any type of pipetting sequence.
- a pipette having 8 channels of a particular volume has been described.
- the pipette may comprise any number of channels of any volume depending on the intended application.
- two extraction systems can be coupled, as illustrated in FIG. 14.
- the rotation handles 50 can be engaged so that two extractions can be conducted simultaneously, the user going up and down the pipettes 12 at the same time.
- the pipettes can also be synchronized, a pipette controlling for example the other pipette.
- the pipette is integrated with a controller that includes programmable pipette up and down and magnet movement (or electromagnet activation / deactivation) mechanisms.
- a controller that includes programmable pipette up and down and magnet movement (or electromagnet activation / deactivation) mechanisms.
- Two washes have been described in the wells of the second row and the third row of the microplate 18a. The number of washings can however be any.
- a single step of capturing particles in the cones One or more particle release steps, each followed by a new capture step, may also be provided.
- the particle capture magnetic field is deactivated by withdrawing the magnetized piece 16 from its housing, and suction / discharge cycles of a tampon are carried out in the pipette cones so as to detach the pellets. particles from the cone walls and disintegrate them.
- suction / discharge cycles of a tampon are carried out in the pipette cones so as to detach the pellets. particles from the cone walls and disintegrate them.
- Such a procedure takes more than 10 minutes to completely detach the caps from the cone walls with a suction / discharge frequency (full suction and discharge in the cones) of 5 cycles per minute.
- a faster release of a pellet 200 is achieved by reciprocating, on the cap 200, the meniscus 300 that forms the pad 302 in a cone 20.
- the suction / discharge cycle is adjusted so that the meniscus 300 makes a limited stroke 304 on either side of the base 200 in order to increase the frequency of passage of the meniscus on the base.
- the frequency of the suction / discharge cycles is increased to further increase said passage frequency, in particular a cycle frequency greater than 2 cycles per second on the presence zone. pellet magnetic particles.
- a full suction / discharge stirring phase in the cones is implemented (eg 8 suction / discharge cycles per minute) to complete to disaggregate the pellets and homogenize the buffer comprising the particles.
- suction / discharge cycles in the wells of the microplates stir a larger volume, over a larger stroke, which facilitates the homogenization of the buffer.
- nucleic acids e.g. DNA and RNA
- This method includes a particle release phase, e.g. as previously described, followed by a buffer wash and particle recapture phase. A significant gain in time is obtained as well as improved extraction.
- this method comprises, once the stage of lysis of the viruses carried out:
- wash buffer eg bioMérieux's "NucliSENS easyMAG Extraction Buffer # 1" 280130.
- Each wash comprises suction / discharge cycles of the wash buffer with particles captured on the pipette tips, and lasts at least 15 seconds, preferably between 25 seconds and 35 seconds, for example 30 seconds, and preferably less than 30 seconds. 'one minute ;
- a third washing step in a third row of the microplate 18a filled with a washing buffer (e.gle "NucliSENS easyMAG Extraction Buffer No. 2" bioMérieux reference bMx 280131).
- a washing buffer e.gle "NucliSENS easyMAG Extraction Buffer No. 2" bioMérieux reference bMx 280131.
- the third washing step preferably comprising a meniscus pass phase on the pellets as described above lasts a few minutes, especially 5 minutes;
- a second step of capturing the particles on the pipette tips eg as described above; 5. optionally a fourth washing step, the particles being captured, in a third row of the microplate 18a filled with a washing buffer (e.gle "NucliSENS easyMAG Extraction Buffer No. 2" bioMérieux reference bMx 280131);
- a washing buffer e.gle "NucliSENS easyMAG Extraction Buffer No. 2" bioMérieux reference bMx 280131
- extraction buffer No. 1 is a buffer promoting the capture of nucleic acids on the silica by creating bridges between the silanol groups of the silica and the phosphate groups of the nucleic acids. It comprises, for example, guanidinium thiocyanate, namely a chaotropic agent as described in the document by R. Boom et al. "Rapid and simple method for purification of nucleic acids.” Journal of Clinical Microbiology. 1989; 28 (3): 495-503;
- the first and second washings make it possible to remove residual debris from the matrix or micro-organisms
- the third and fourth washings make it possible to eliminate traces of GuSCN and inhibitors of a PCR type amplification which is usually subsequently put in place on the DNA / RNA captured by the magnetic particles.
- the elution buffer included in the PCR cones makes it possible to remove all traces of washing buffer and to be in the optimal conditions for the elution step
- the following table compares the results obtained with the device according to the invention by applying the protocol just described (first 2 wash followed by a third wash with release of the particles) in comparison with the results obtained with a device of the state. of the technique, namely the MiniMag® marketed by bioMérieux and considered as a reference device in the viral RNA extraction.
- the protocol for the MiniMag® includes four washing steps with wash buffers (two with the "NucliSENS easyMAG Extraction Buffer # 1" buffer and two with the "NucliSENS easyMAG Extraction Buffer # 2" buffer).
- a real-time PCR (or "q-PCR") amplification of the extracted lysate is implemented and the Ct ("cycle threshold", which quantifies a nucleic acid detection threshold in one sample) of each measured sample.
- the samples tested in duplicate are 25-gram samples of raspberry or green onion supplemented with a solution of pure Mengo virus (corresponding to 500 copies of the genome per gram) or diluted to 1/10 th .
- Invention (Ct value)
- MiniMag ® Ct value
- the extraction of the viral RNA according to the invention gives similar results with those obtained using the MiniMag®.
- tests were conducted with different batches of magnetic silica particles of various quality. It has been found that the extraction according to the invention is surprisingly very robust vis-à-vis the quality of said particles.
- tests were carried out on the same samples with a batch of particles of lesser performance, the extraction not having the release / washing / recapture step as described above. In this case, the extraction rate was lower. Using the preferred method described above with the defective particles, results similar to those of the previous table were obtained.
- nucleic acids eg RNA and / or DNA from a lysis performed prior to the capture / washing / migration and transfer phases.
- the invention is also applicable to the capture of microorganisms (eg bacteria, fungi, yeasts) using magnetic particles whose surface is functionalized to capture microorganisms (eg coated with phage proteins or polycations capable of such capture in a manner known per se).
- the magnetic particles with their captured microorganisms are transferred into tubes for subsequent lysis, for example mechanical.
- the lysate obtained can be directly treated, for example a polymerase chain reaction amplification (eg q-PCR quantitative PCR), or be purified according to the nucleic acid extraction method described. previously.
- the invention is particularly suitable for microbial sample preparation for PCR.
- the sample on which the capture of particles in the pipette cones is carried out can be of very large volume (eg several milliliters) whereas the final volume of the tubes in which the particles are transferred can be of very small volume (eg less than or equal to 200 micro liters, or even less than or equal to 100 micro liters).
- the large volume of the sample a significant number of microorganism is captured.
- the transition to a very small final volume has the effect of concentrating microorganisms.
- the inventors have noted that a single capture phase from a sample of a few milliliters followed by a single washing step, is sufficient to obtain results by q-PCR from a lysis performed in a volume of 5 ml. microliters.
- enrichment of food matrix (chicken needle) in nutrient broth was performed for 5 hours at 41.5 ° C.
- a post-contamination with a Salmonella Derby strain is carried out at a level of 10 2 to 10 4 CFU / mL, which corresponds to concentrations that can be reached after enrichment in the presence of pathogen in the food matrix (ie concentrations for which a food lot is determined to be unsuitable for consumption).
- concentrations for which a food lot is determined to be unsuitable for consumption concentrations for which a food lot is determined to be unsuitable for consumption.
- two procedures are performed in duplicate, one according to the standardized capture protocol with the Gene-up® system from bioMérieux, France, and one according to the invention.
- the Gene-up protocol consists of a step of "bead-beating" of the sample (ie mechanical disruption of the bacterial wall), taking 20 of it from a bead-beating tube containing 180 wash buffer, followed by stirring for 5 minutes on microplate shaker for bead-beating. 5 microliters of the final solution are taken and then subjected to q-PCR.
- the process according to the invention consists of:
- the estimated sensitivity gain is 2 log compared to the standard Gene-UP protocol.
- the present invention addresses a problem of versatility for the use of different magnetic capture techniques (purification of nucleic acids, magnetic immuno-concentration, etc.).
- the system according to the invention which is scalable and can be modulated, makes it possible: to carry out steps of capture / washing / elution of magnetic particles by using an autonomous system constituted by the combination of a programmable electronic pipette and a support allowing carrying out the various steps mentioned above;
- the elution steps can be carried out in different types of tubes: 0.2 mL PCR tubes for recovering magnetic silica particles when it is It acts of capture of the nucleic acids (eg NucliSENS ⁇ chemistry) or of bead-beating tubes in the case of the recovery of magnetic particles used for the recovery of pathogens (Magnetic Immuno-Concentration).
- the system allows the realization of pathogen capture / concentration steps on the magnetic particles and their in-situ lysis using ceramic / glass beads (e.g. CapLyse ⁇ type process).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Clinical Laboratory Science (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Sustainable Development (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Sampling And Sample Adjustment (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16168001.2A EP3241901B1 (en) | 2016-05-03 | 2016-05-03 | Method and system for magnetic extraction of components in a liquid sample |
EP16180724 | 2016-07-22 | ||
PCT/EP2016/078905 WO2017190816A1 (en) | 2016-05-03 | 2016-11-25 | Method and system for magnetic extraction of components in a liquid sample |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3452589A1 true EP3452589A1 (en) | 2019-03-13 |
EP3452589B1 EP3452589B1 (en) | 2021-01-06 |
Family
ID=57396464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16801505.5A Active EP3452589B1 (en) | 2016-05-03 | 2016-11-25 | Method and system for magnetic extraction of components in a liquid sample |
Country Status (9)
Country | Link |
---|---|
US (2) | US11572553B2 (en) |
EP (1) | EP3452589B1 (en) |
JP (2) | JP6861222B2 (en) |
KR (1) | KR20190003728A (en) |
CN (1) | CN109072230B (en) |
CA (1) | CA3023112C (en) |
ES (1) | ES2862393T3 (en) |
RU (1) | RU2721121C1 (en) |
WO (1) | WO2017190816A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023139323A1 (en) * | 2022-01-18 | 2023-07-27 | Biomerieux | Module for magnetically extracting components from a sample |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5234809A (en) * | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
US20030012699A1 (en) * | 1998-11-18 | 2003-01-16 | Thomas Moore | Simultaneous handling of magnetic beads in a two-dimensional arrangement |
JP4045475B2 (en) * | 1999-09-06 | 2008-02-13 | 東洋紡績株式会社 | Nucleic acid / protein purification equipment |
FR2826882B1 (en) * | 2001-07-09 | 2003-09-12 | Bio Merieux | PROCESS FOR THE TREATMENT OF MAGNETIC PARTICLES AND CONFIGURATIONS OF MAGNETS ALLOWING THE IMPLEMENTATION OF THIS PROCESS |
JP2003149255A (en) * | 2001-11-15 | 2003-05-21 | Toyobo Co Ltd | Dispensing device movable to rectangular coordinate and cyclinderical coordinate |
US20050239091A1 (en) * | 2004-04-23 | 2005-10-27 | Collis Matthew P | Extraction of nucleic acids using small diameter magnetically-responsive particles |
DE502005003212D1 (en) * | 2004-05-10 | 2008-04-24 | Bernd Steinbrenner | DEVICE FOR RECEIVING AND DISTRIBUTING LIQUIDS |
EP1621890A1 (en) * | 2004-07-26 | 2006-02-01 | bioMerieux B.V. | Device and method for separating, mixing and concentrating magnetic particles with a fluid and use thereof in purification methods |
GB2425498A (en) | 2005-04-25 | 2006-11-01 | Dynal Biotech Asa | A magnetic separation device |
DE102005053463A1 (en) * | 2005-11-06 | 2007-05-10 | Aj Innuscreen Gmbh | Apparatus and method for the automated isolation and purification of nucleic acids from any complex starting materials |
TWI415770B (en) * | 2006-01-13 | 2013-11-21 | Universal Bio Research Co Ltd | Variable form dispensing tube, deformation type dispensing device and deformation type dispensing processing method |
WO2007094506A1 (en) * | 2006-02-15 | 2007-08-23 | Tosoh Corporation | Method for extraction of nucleic acid from biological material |
US7998708B2 (en) * | 2006-03-24 | 2011-08-16 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US7662343B2 (en) | 2006-10-24 | 2010-02-16 | Viaflo Corporation | Locking pipette tip and mounting shaft |
US8163183B2 (en) * | 2007-02-07 | 2012-04-24 | Universal Bio Research Co., Ltd. | Magnetic particle parallel processing apparatus permitting repeated use of container and method of magnetic particle parallel processing permitting repeated use of container |
JP2008220260A (en) * | 2007-03-13 | 2008-09-25 | Hitachi Metals Ltd | Method for magnetic separation of magnetic particle |
US8033188B2 (en) | 2007-09-17 | 2011-10-11 | Integra Biosciences Corp. | Pipettor software interface |
US7540205B2 (en) | 2007-09-17 | 2009-06-02 | Viaflo Corp. | Electronic pipettor |
US8277757B2 (en) * | 2009-09-29 | 2012-10-02 | Integra Biosciences Corp. | Pipette tip mounting shaft |
EP2565260B1 (en) | 2010-04-30 | 2020-12-23 | Bioneer Corporation | Automatic biological sample purification device having a magnetic-field-applying unit, a method for extracting a target substance from a biological sample, and a protein expression and purification method |
CN102417902A (en) * | 2011-09-16 | 2012-04-18 | 广西出入境检验检疫局检验检疫技术中心 | Kit for extracting nucleic acid by magnetic bead-microtiter plate method and method for extracting nucleic acid by same |
JP2012152213A (en) * | 2012-02-14 | 2012-08-16 | Tamagawa Seiki Co Ltd | Device for aggregating/dispersing magnetic particle in liquid |
FR2997703B1 (en) * | 2012-11-07 | 2016-12-30 | Biomerieux Sa | PROCESS FOR TREATING AT LEAST ONE BIOLOGICAL SAMPLE |
FR2999012B1 (en) * | 2012-11-30 | 2017-12-15 | Primadiag S A S | MAGNETIC ATTRACTION MODULE, ROBOT COMPRISING SUCH A MODULE, AND METHOD FOR USE ON MAGNETIC BALLS OF SUCH A MODULE OR ROBOT |
-
2016
- 2016-11-25 RU RU2018142267A patent/RU2721121C1/en active
- 2016-11-25 US US16/098,095 patent/US11572553B2/en active Active
- 2016-11-25 KR KR1020187034993A patent/KR20190003728A/en not_active Application Discontinuation
- 2016-11-25 CN CN201680085380.0A patent/CN109072230B/en active Active
- 2016-11-25 EP EP16801505.5A patent/EP3452589B1/en active Active
- 2016-11-25 CA CA3023112A patent/CA3023112C/en active Active
- 2016-11-25 JP JP2018557781A patent/JP6861222B2/en active Active
- 2016-11-25 WO PCT/EP2016/078905 patent/WO2017190816A1/en active Application Filing
- 2016-11-25 ES ES16801505T patent/ES2862393T3/en active Active
-
2020
- 2020-11-27 JP JP2020197234A patent/JP7482005B2/en active Active
- 2020-12-03 US US17/110,436 patent/US11584926B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3023112C (en) | 2023-03-21 |
JP2019516369A (en) | 2019-06-20 |
CA3023112A1 (en) | 2017-11-09 |
US11572553B2 (en) | 2023-02-07 |
US20210115433A1 (en) | 2021-04-22 |
WO2017190816A1 (en) | 2017-11-09 |
EP3452589B1 (en) | 2021-01-06 |
US20190316114A1 (en) | 2019-10-17 |
US11584926B2 (en) | 2023-02-21 |
ES2862393T3 (en) | 2021-10-07 |
CN109072230A (en) | 2018-12-21 |
JP2021063811A (en) | 2021-04-22 |
RU2721121C1 (en) | 2020-05-18 |
JP7482005B2 (en) | 2024-05-13 |
CN109072230B (en) | 2023-07-21 |
JP6861222B2 (en) | 2021-04-21 |
KR20190003728A (en) | 2019-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040126783A1 (en) | Apparatus and method for isolating a nucleic acid from a sample | |
JP5292267B2 (en) | SAMPLE PROCESSING DEVICE, SAMPLE PROCESSING METHOD, AND REACTION CONTAINER USED FOR THEM | |
US9650626B2 (en) | Kit for nucleic acid extraction and a nucleic acid extractor | |
US20110009608A1 (en) | Automatic refining apparatus, multi-well plate kit and method for extracting hexane from biological samples | |
JP4643008B2 (en) | Concentration apparatus and method using magnetic particles | |
WO2003033740A2 (en) | Apparatus and method for isolating a nucleic acid | |
EP2222403A2 (en) | Sample preparation devices and analyzers | |
KR101707987B1 (en) | Automatic quantitative dispensing device, continuous type gene extraction-amplification apparatus including the device and operating method of the apparatus | |
EP3241901B1 (en) | Method and system for magnetic extraction of components in a liquid sample | |
FR3058734A1 (en) | EXTRACTION SYSTEM AND METHOD FOR EXTRACTING MICROORGANISMS FROM A SAMPLE | |
CA3023112C (en) | Method and system for magnetic extraction of components in a liquid sample | |
JP2011234671A (en) | Nucleic acid extraction device | |
CN108603221A (en) | Comprehensive sample processing system | |
EP2926144B1 (en) | Magnetic attraction module, robot including such a module, and method for using such a module or such a robot on magnetic beads | |
JP5599488B2 (en) | Sample processing method | |
FR3098417A1 (en) | AUTOMATIC DEVICE FOR THE EXTRACTION OF BIOLOGICAL COMPONENTS FROM MULTIPLE SAMPLES, PERFORMING TWO DISTINCT SEPARATION METHODS, CENTRIFUGATION AND MAGNETIC FIELD | |
BE1030466B1 (en) | DEVICE AND METHOD FOR THE SEPARATION AND/OR PURIFICATION OF A COMPOUND OF INTEREST | |
EP3938114B1 (en) | Method and apparatus for magnetic bead manipulation | |
WO2016132028A1 (en) | Device for collecting biological material from a biological trace |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181112 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20191121 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200827 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOMERIEUX |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1352402 Country of ref document: AT Kind code of ref document: T Effective date: 20210115 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016051100 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1352402 Country of ref document: AT Kind code of ref document: T Effective date: 20210106 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210506 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210406 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210406 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210506 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016051100 Country of ref document: DE Ref country code: ES Ref legal event code: FG2A Ref document number: 2862393 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211007 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
26N | No opposition filed |
Effective date: 20211007 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210506 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211125 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211130 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20211130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211125 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230523 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20161125 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20231126 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231127 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231201 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20231122 Year of fee payment: 8 Ref country code: FR Payment date: 20231127 Year of fee payment: 8 Ref country code: DE Payment date: 20231129 Year of fee payment: 8 Ref country code: CH Payment date: 20231201 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |